Clinical trial
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or…
NCT00112502 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00112502 |
|---|---|
| Title | Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme |
| Official title | A Randomized, Factorial-Design, Phase II Trial of Temozolomide Alone and in Combination With Possible Permutations of Thalidomide, Isotretinoin and/or Celecoxib as Post-Radiation Adjuvant Therapy of Glioblastoma Multiforme |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors, Glioblastoma Multiforme |
| Intervention type | Drug |
| Interventions | Celecoxib, Isotretinoin, Temozolomide, Thalidomide |
| Enrollment | 178 |
| Start date | Sep 1, 2005 |
| Primary completion | Sep 1, 2014 |
| Completion | Sep 1, 2014 |
| First posted | Jun 3, 2005 |
| Last update posted | Oct 18, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: